Whitehawk Therapeutics (WHWK) Research & Development (2016 - 2026)
Whitehawk Therapeutics (WHWK) posted quarterly Research & Development of $17.2 million for Q1 2026, up 96.09% year-over-year from $8.8 million in Q1 2025, and down 9.41% quarter-over-quarter from $19.0 million in Q4 2025.
Whitehawk Therapeutics (WHWK) Research & Development (2016 - 2026) Analysis & Trends
Whitehawk Therapeutics (WHWK) has reported Research & Development for 11 consecutive years, with $17.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development rose 96.09% year-over-year to $17.2 million; the TTM figure through Mar 2026 stood at $99.4 million (up 115.05% YoY), while the FY2025 annual figure was $91.0 million, up 78.25% from the prior year.
- Research & Development slipped to $17.2 million in Q1 2026 per WHWK's latest filing, from $19.0 million in the prior quarter.
- Across five years, Research & Development topped out at $48.8 million in Q2 2025 and bottomed at $6.8 million in Q1 2022.
- Historically, Research & Development has averaged $14.2 million across 5 years, with a median of $12.8 million in 2023.
- On a YoY basis, Research & Development climbed as much as 272.79% in 2025 and fell as far as 35.35% in 2025.
- Whitehawk Therapeutics' Research & Development stood at $9.4 million in 2022, then soared by 36.26% to $12.8 million in 2023, then rose by 12.37% to $14.3 million in 2024, then jumped by 32.58% to $19.0 million in 2025, then retreated by 9.41% to $17.2 million in 2026.
- Business Quant data shows WHWK's Research & Development at $17.2 million in Q1 2026, $19.0 million in Q4 2025, and $14.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Whitehawk Therapeutics | 369.67 Mn | 74.92 Mn | - | 12.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.89 Mn |
| Mar 31, 2026 | 17.23 Mn |
| Dec 31, 2025 | 19.02 Mn |
| Sep 30, 2025 | 14.35 Mn |
| Jun 30, 2025 | 48.81 Mn |
| Mar 31, 2025 | 8.79 Mn |
| Dec 31, 2024 | 14.35 Mn |
| Sep 30, 2024 | 10.00 Mn |
| Jun 30, 2024 | 13.09 Mn |
| Mar 31, 2024 | 13.59 Mn |
| Dec 31, 2023 | 12.77 Mn |
| Sep 30, 2023 | 11.89 Mn |
| Jun 30, 2023 | 13.32 Mn |
| Mar 31, 2023 | 10.96 Mn |
| Dec 31, 2022 | 9.37 Mn |
| Sep 30, 2022 | 8.77 Mn |
| Jun 30, 2022 | 7.73 Mn |
| Mar 31, 2022 | 6.79 Mn |
| Dec 31, 2021 | 7.23 Mn |
| Sep 30, 2021 | 5.75 Mn |